

[0004] In some cases, the compound has the following chemical structure:




(II).

[0004a] Provided herein, in some asepcts, is a use of a pharmaceutical composition in the manufacture of a medicament for treating or reducing the likelihood of developing a disease or condition characterized by a reduced expression or function of $Na_V1.1$ protein in a human subject in need thereof, wherein the pharmaceutical composition is to be administered to the human subject, wherein the pharmaceutical composition comprises a compound according to the following chemical structure:



(I), or a salt thereof.

[0004b] Provided herein, in some aspects, is a pharmaceutical composition comprising a compound according to the following chemical structure:



(I), or a salt thereof for use in therapy.

[0005] Provided herein, in some aspects, is a method of treating or reducing the likelihood of developing a disease or condition characterized by a reduced expression or function of $Na_V1.1$ protein in a human subject in need thereof, the method comprising administering to the human subject a pharmaceutical composition comprising a compound according to chemical structure (I) as aforementioned, or a salt thereof, thereby treating or reducing the likelihood of developing the disease or condition in the human subject. In some cases, the compound has chemical structure (II) as aforementioned.

[0006] Provided herein, in some aspects, is a pharmaceutical formulation comprising: (a) a compound according to chemical structure (I) as aforementioned, or a salt thereof; and (b) a pharmaceutically acceptable diluent, and wherein the compound is dissolved or suspended in a solution. In some cases, the compound has chemical structure (II) as aforementioned.

[0007] Provided herein, in some aspects, is a kit comprising: (i) an concentrate comprising a compound according to chemical structure (I) as aforementioned, or a salt thereof; and (ii) a diluent, wherein the concentrate is miscible with the diluent; and (iii) instructions for diluting or solubilizing the compound in the diluent. In some cases, the compound has chemical structure (II) as aforementioned.

[0008] Provided herein, in some aspects, is a use of a compound for the manufacture of a medicament for treating or preventing a disease or condition characterized by a reduced expression or function of $Na_V1.1$ protein in a human subject in need thereof, and wherein the compound is according to chemical structure